Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Ketamine's Actions on Rumination Mechanisms as an Antidepressant


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04656886

Organisation Name: King's College London

Overal Status: Completed

Start Date: September 2014

Last Update: December 7, 2020

Lead Sponsor: King's College London

Brief Summary: Rumination and anhedonia are two of the most common characteristics of depression that persist during remission and are not easily targeted by commonly prescribed antidepressants. Ketamine, an NMDA receptor antagonist, has emerged within the last decade as a potent, fast-acting antidepressant that can significantly improve anhedonia as early as two hours after a single infusion. The brain mechanisms, however, by which ketamine exerts its antidepressant action remain largely unknown. The aim of this study is to examine the early antidepressant action of ketamine, 2h post infusion, in patients who remitted from depression using fMRI. Participants are scanned while performing a personalised, autobiographical, emotional memory task and a monetary reward task. Ketamine is expected to reduce the activation of limbic areas such as the amygdala during emotional memory recall. Increased activations after ketamine are expected in reward processing areas, including striatal regions.

Conditions:
  • Remission in Depression


Total execution time in seconds: 0.17118716239929